Makrofaj Migrasyon İnhibitör Faktör Değerlerinin Tekrarlayan Aftöz Stomatit Hastalığıyla İlişkisi

Year 2014, Volume: 2 Issue: 2, 77 - 80, 16.11.2015

Mehmet Yanık , Gamze Erfan Feti Tülübaş Mustafa Oran Mustafa Kulaç

Abstract

Özet
Giriş
Tekrarlayan aftöz stomatit(TAS) en sık görülen mukozal hastalıktır ve etyolojisi bilinmemektedir. Makrofaj inhibisyon faktör(MIF) T hücre aktivasyonunda önemli rolü olan proinflamatuar bir sitokindir. Çalışmamızda MIF’in TAS etyolojisindeki önemi incelenmiştir.
Materyal-Metod
Çalışmaya polikliniğimize başvuran 18 yaşından büyük 70 TAS hastası ve 44 adet gönüllü olmak üzere toplam 114 kişi dahil edilmiştir. Hasta ve kontrol grubu serum MIF değerleri ELISA ile değerlendirilmiştir.
Bulgular
TAS grubunda ortalama MIF değeri ile kontrol grubunda ortalama MIF değerleri açısından anlamlı fark bulunamamıştır. TAS skoru 5 ve altında olanlar ile 6 ve üzeri olanlar MIF değeri açısından karşılaştırılmıştır ve istatistiksel olarak anlamlı fark bulunamamıştır. Rekürrens sıklığı ve MIF değerleri arasında anlamlı fark bulunamamıştır.
Sonuç
MIF’in TAS hastalığında da etyolojik faktörler arasında olabileceğini düşünerek yaptığımız çalışmada istatistiksel olarak anlamlı bir sonuç elde edemedik.


Abstract
Introduction
Recurrent aphtous stomatitis (RAS) is the most common mucosal disease with unknown etiology. Macrophage inhibition factor(MIF) is a proinflamatory cytokine which has a role in T cell activation. This study aimed to investigate importance of MIF in etiology of RAS.
Material and Methods
70 patients who were above the age of 18, clinically diagnosed RAS and 72 healthy volunteers were included into the study. Patients and control subjects were examined for MIF seroprevalence by ELISA.
Results
There were no significant difference between RAS and control groups in mean values of MIF. In comparison of RAS patients in two subgroups- with RAS score above 6 and with 5 and less than 5, there were also no significant difference between these subgroups in mean values of MIF. On the other hand; the reccurrence of lesions and mean values of MIF showed no relevance.
Conclusion
Eventhough proposed in the hypothesis of this study, there had been no statistically significant relationship between MIF and RAS etiology.

Keywords

Tekrarlayan aftöz stomatit, Makrofaj migrasyon inhibitör faktör, T hücre

References

• Jurge S, Kuffer R, Scully C, Porter SR. Mucosal Diseases Series, Number VI Recurrent aphthous stomatitis. Oral Dis 2006;12(1):1-21.
• Shulman JD. An exploration of point, annual, and in lifetime aphthous stomatitis in USA children and youths. J Oral Pathol Med. 2004; 33(9):558–66.
• characterizing recurrent
• Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am. 2005;49(1):31-47.
• Chavan M, Jain H, Diwan N, Khedkar S, Shete A, Durkar S. Recurrent aphthous stomatitis: a review. J Oral Pathol Med. 2012;41(8):577-83.
• Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005;37(2):65- 73.
• Onodera S, Tanji H, Suzuki K, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 1999;11(2):163- 7.
• Leech M, Metz C, Santos L, et al. Involvement of macrophage migration inhibitory factor in the evolution of 1998;41(5):910-7. Arthritis Rheum
• Hoi AY, Morand EF, Leech M. Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus? Immunol Cell Biol. 2003;81(5):367-73.
• Foote A, Kipen Y, Santos L, et al. Macrophage migration erythematosus. J Rheumatol. 2004;31(2):268-73.
• Meyer-Siegler K, Hudson PB. Enhanced expression of factor in systemic lupus macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996;48(3):448- 52.
• Mumcu G, Sur H, Inanc N, et al. A composite index for determining the impact of oral ulcer activity in behcet's disease and recurrent aphthous stomatitis. J Oral Pathol Med 2009;38(10):785-91
• Shimizu T, Abe R, Ohkawara A, Nishihira J. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immunol 1999;104(3):659-64.
• Shimizu T, Nishihira J, Mizue Y, et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol. 2001;116(6):989-90.
• Ma L, Xue HB, Guan XH, et al. Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris. Braz J Med Biol Res 2013;46(5):460-4.
• Shimizu T, Mizue Y, Abe R, Watanabe H, Shimizu H. Increased macrophage migration inhibitory factor (MIF) in the sera of patients with extensive alopecia areata. J Invest Dermatol 2002;118(3):555-7.
• Younan DN, Agamia N, Elshafei A, Ebeid N. Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease. J Clin Lab Anal doi: 10.1002/jcla.21731. [Epub ahead of print]